Drug Security Forum

The policy of import substitution was established back in the early stages of development of the domestic pharmaceutical industry. Today, in the context of global challenges, the issue of drug security is no longer a theory, but a modern Russian reality. The national pharmaceutical industry is faced with the task of developing timely strategies to respond to the current agenda, the highest priority requirements of which include ensuring continuity of supply of strategically important medicines and medical devices, achieving technological sovereignty for the industry, and maintaining competitiveness in foreign markets, which the biggest Russian manufacturers have successfully achieved. What are Russian companies preparing for today, what kind of strategies are they choosing, and to what extent do those tally with the government’s demands? Is it possible to talk about trends in intensifying production cycles? What barriers currently stand in the way of achieving technological sovereignty? What measures can support the development of high-tech exports now that sanctions have been imposed? Are Russian producers ready to develop new markets and competences? What role do state corporations and large holding companies play in developing the production of materials, components, and raw materials?

Moderator
Aleksandr Petrov, Head of the Expert Council for Regulating the Circulation of Medicines and Medical Devices, Committee of the State Duma of the Federal Assembly of the Russian Federation on Health Protection

Aleksandr Petrov

Head of the Expert Council for Regulating the Circulation of Medicines and Medical Devices, Committee of the State Duma of the Federal Assembly of the Russian Federation on Health Protection

Panellists
Darya Borisova, Member of the Board – Managing Director for Development and Innovations, SIBUR
Alexander Braverman, First Deputy Chairman, VEB.RF
Dmitriy Galkin, Director of Department of Pharmaceutical and Medical Industry Development, Ministry of Industry and Trade of the Russian Federation
Danica Grujicic, Minister of Health of the Republic of Serbia
Rajiv Kumar, General Director, Raymed Trading Group
Victor Fisenko, First Deputy Minister of Health of the Russian Federation (online)
Evgeniya Shapiro, Director General, PSK Pharma

Darya Borisova

Member of the Board – Managing Director for Development and Innovations, SIBUR

Education:
Graduated from the Faculty of Chemistry, Moscow State University, and the University of Toledo, USA. She holds a PhD in Physical Chemistry.
All positions held during the last five years:
Before joining SIBUR, was Senior Partner at McKinsey. One of the founders of the firm’s petrochemical and oil and gas practice in Russia and the CIS, she led McKinsey's expert team for operational and investment efficiency improvements across industrial companies in Russia, CIS, Turkey, Middle East and Africa.
Since November 2019, member of the Management Board – Managing Director at SIBUR LLC.

Alexander Braverman

First Deputy Chairman, VEB.RF

Dmitriy Galkin

Director of Department of Pharmaceutical and Medical Industry Development, Ministry of Industry and Trade of the Russian Federation

Danica Grujicic

Minister of Health of the Republic of Serbia

Rajiv Kumar

General Director, Raymed Trading Group

Victor Fisenko

First Deputy Minister of Health of the Russian Federation

Evgeniya Shapiro

Director General, PSK Pharma

Front row participant
Vsevolod Belousov, Director, "Federal Center of Brain Research and Neurotechnologies" of the Federal Medical Biological Agency

Vsevolod Belousov

Director, "Federal Center of Brain Research and Neurotechnologies" of the Federal Medical Biological Agency

Born on February 19, 1975 in Nalchik, KBR.
Graduated from the Faculty of Biology, Lomonosov Moscow State University in 1998.
D. in Biology (2013), Professor of the Russian Academy of Sciences, Head of the Department of Metabolism and Redox Biology of the Institute of Biochemistry of the Russian Academy of Sciences, Professor at the University of Göttingen.
Vsevolod Belousov is a scientist known in Russia and worldwide, a specialist in synthetic biology, molecular neurotechnology, and biomedicine. Biosensor and bioengineering technologies developed by Vsevolod Belousov are used by hundreds of laboratories worldwide. One of the main areas of Belousov's research is thermogenetics: controlling the activity of neurons and other cells by means of temperature-sensitive ion channels. Thermogenetic technologies are being developed to activate the brain, heart and pancreas. Another area of research is metabolic engineering - creation of artificial metabolic pathways in cells. For the development of technology to manage oxidative stress at the subcellular level and its application to study the mechanisms of heart failure, Vsevolod Belousov was awarded the Discovery Award-2019 by the Society for Redox Biology and Medicine in the USA.
Since 2019, Vsevolod Belousov has headed the Federal Brain and Neurotechnology Center of the Federal Medical and Biological Agency of Russia, a flagship scientific-clinical center that conducts research on pathologies of the nervous system and provides high-tech medical care in the profiles of neurology, neurorehabilitation, and neurosurgery. In the first wave of the Covid-19 pandemic, the Center was converted to an infectious disease hospital to treat patients with the new coronavirus infection. Vsevolod Belousov was awarded the Silver Cross of the Federal Medical and Biological Agency of Russia for successful organization of the clinic's work during the pandemic.